Important Notice and Disclaimer.

No Offer; Not Investment Advice

This website is provided by Cyphaira Corp. (formerly Growth Stalk Holdings Corp) (the "Company") for informational purposes only. Nothing on it is an offer to sell, or a solicitation of an offer to buy, any security, and nothing on it is investment, legal, tax, or regulatory advice. Any offering of securities will be made only through appropriate offering documents and only in compliance with applicable securities laws. Investors should not rely on this website in making an investment decision. They should review the Company's disclosure documents at www.otcmarkets.com/stock/CYPA/disclosure and consult their own advisors.

Reporting Status

The Company provides disclosure under OTC Markets Group's Alternative Reporting Standard and has done so beginning with its quarterly report for the period ended March 31, 2024. The Company is not subject to the periodic reporting requirements of the Securities Exchange Act of 1934 and does not file reports with the SEC. Information about the Company may therefore be more limited than for SEC reporting companies.

Forward-Looking Statements

This website contains forward-looking statements. They include statements about the Company's corporate name change; the development, testing, commercialization, features, and market acceptance of SolvixLMS and any future products; the possible use of artificial intelligence or machine learning; expansion into other markets; patent protection; and the effect of federal or state cannabis regulation; and the contemplated divestiture of the Company's cannabis subsidiaries. Words such as "anticipate," "believe," "expect," "intend," "plan," "thesis," "roadmap," "vision," "becoming," and similar expressions identify these statements. They are based on current expectations and assumptions and are subject to significant risks and uncertainties, and actual results may differ materially. Because the Company is an issuer of penny stock, the safe harbor for forward-looking statements under the Private Securities Litigation Reform Act of 1995 is not available to it. The Company undertakes no obligation to update any statement, except as required by law.

Product Status

SolvixLMS is in alpha testing. It is not commercially available and has generated no revenue. The alpha is being conducted at a facility operated by Southbound Sunshine, LLC, [an affiliate of the Company]. Alpha results may not predict commercial performance. There is no assurance SolvixLMS will be commercially released, adopted by unaffiliated customers, or generate revenue. SolvixLMS does not currently incorporate artificial intelligence or machine learning. Any future capability is a development goal that may never be achieved. The Company makes no representation that SolvixLMS satisfies any federal or state recordkeeping, reporting, or compliance requirement.

Intellectual Property

The Company has filed U.S. Provisional Patent Application No. 63/904,128. A provisional application is not examined, confers no enforceable rights, and expires unless a non-provisional application is timely filed. There is no assurance a patent will issue.

Cannabis Regulatory Risk

Cannabis remains a controlled substance under U.S. federal law. The April 2026 federal order placed only FDA-approved products and marijuana subject to a qualifying state medical marijuana license in Schedule III. It did not reschedule recreational or unlicensed cannabis, and federal authorization requires DEA registration in addition to state licensure. The Company's subsidiary [has/has not] obtained DEA registration. The DEA administrative proceeding on broader rescheduling is ongoing. Its outcome, and any legal challenge to it or to the April 2026 order, is uncertain and could adversely affect the Company. The Company's cannabis operations remain subject to federal enforcement, banking, and tax risks. The Company's cannabis subsidiaries are the subject of a contemplated divestiture that has not been finalized, requires state regulatory approvals, and may not be completed.

Third-Party and Market Information

Statements about industry size, competitors, and the Company's relative position reflect management's beliefs or third-party sources that the Company has not independently verified.

Risk

An investment in the Company is speculative and involves a high degree of risk, including the possible loss of the entire investment. Risks include limited operating history in software, lack of revenue from SolvixLMS, need for additional capital, dilution, reliance on key personnel, and limited trading liquidity and price volatility in the Company's common stock. [The Company's financial statements include disclosure regarding substantial doubt about its ability to continue as a going concern.] Outstanding convertible notes, warrants and settlement obligations may result in the issuance of a substantial number of additional shares, and the Company may effect a reverse stock split.

No Paid Promotion

The Company has not paid any person to promote its securities in connection with this website.

See also Privacy and Terms of Use.